Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | May 23, 2019 | May 24, 2019 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2024 | January 04, 2024 |
| QuidelOrtho CorpQDEL · Entity 4986 | President and CEO | May 15, 2026 | May 19, 2026 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | Director | May 17, 2022 | August 30, 2022 |
| Talis Biomedical CorpTLIS · Entity 87664 | Director · President and CEO | December 01, 2021 | December 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 23, 2019 · Filed May 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 130,745 |
Ending reported balance
After 2019-05-23 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-05-23 · Exercise / conversion · Acquired 165,000 · Balance 295,745 Row 2 · 2019-05-23 · Exercise / conversion · Acquired 175,164 · Balance 470,909 Row 3 · 2019-05-23 · Exercise / conversion · Acquired 53,163 · Balance 524,072 Row 4 · 2019-05-23 · Exercise / conversion · Acquired 56,735 · Balance 580,807 Row 5 · 2019-05-23 · Sale · Disposed 450,062 · Balance 130,745 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.94 · Expires 2023-02-14 | Direct | 0 |
Reported balance
After 2019-05-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-05-23 · Exercise / conversion · Disposed 165,000 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.12 · Expires 2024-02-20 | Direct | 0 |
Reported balance
After 2019-05-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-23 · Exercise / conversion · Disposed 175,164 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 120,000 |
Reported balance
After 2019-05-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-05-23 · Exercise / conversion · Disposed 53,163 · Balance 120,000 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2026-02-18 | Direct | 300,000 |
Reported balance
After 2019-05-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-05-23 · Exercise / conversion · Disposed 56,735 · Balance 300,000 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Quanterix Corp
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,049 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 2,947 · Balance 19,049 F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 19,049 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-01-02 | Direct | 6,412 |
Reported balance
After 2024-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-02 · Grant · Acquired 6,412 · Balance 6,412 F3: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 19,049 restricted stock units.
F3: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.
QuidelOrtho Corp
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,649 |
Ending reported balance
After 2026-05-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-15 · Grant · Acquired 20,759 · Balance 45,901 F1: Reflects release of restricted stock units that were previously reported on a Form 3. Row 2 · 2026-05-15 · Tax withholding · Disposed 10,252 · Balance 35,649 F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,759 |
Reported balance
After 2026-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-15 · Exercise / conversion · Disposed 20,759 · Balance 20,759 F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 40,073 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,073 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 3.
F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F4: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027.
Rockley Photonics Holdings Ltd
Report date May 17, 2022 · Filed August 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 65,322 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 65,322 · Balance 65,322 F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control.
Talis Biomedical Corp
Report date December 01, 2021 · Filed December 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2031-11-30 | Direct | 750,000 |
Reported balance
After 2021-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-01 · Grant · Acquired 750,000 · Balance 750,000 F1: 20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 625,000 |
Reported balance
After 2021-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-01 · Grant · Acquired 625,000 · Balance 625,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting. F3: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting.
F3: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2010 Filed Jul 22, 2010 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 44 | $47.24 | $2,078.56 |
DisclosureSEC source: 0001179110-10-011813 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,387 Read SEC document |
| July 20, 2010 Filed Jul 22, 2010 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 128 | $47.41 | $6,068.48 |
DisclosureSEC source: 0001179110-10-011813 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,431 Read SEC document |
| May 17, 2010 Filed May 19, 2010 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 19,000 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001179110-10-008958 · edgar.xml · derivative · entry 4 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common shares · 19,000 shares Expires 2020-05-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,334 on 5/17/2011, 6,333 on 5/17/2012, and 6,333 on 5/17/2013. Read SEC document |
| May 17, 2010 Filed May 19, 2010 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008958 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,559 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The award vests on the third anniversary of the grant date and includes the right to have stock withheld for tax purposes. Read SEC document |
| May 17, 2010 Filed May 19, 2010 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008958 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,559 F1 · shares: These shares represent a performance vested restricted stock award under the Abbott Laboratories 2009 Incentive Stock Program. The award has a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.